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Background: Sensitive and selective analytical method is required for the estimation of lovastatin in human plasma as
lovastatin has been reported to have high intra-subject variability and is converted to its active metabolite lovastatin
hydroxy acid in in vitro system and vice versa. If this inter-conversion is not restricted, it could lead to pseudo estimation
of lovastatin in human plasma.
Methods: A specific, sensitive, and reproducible high-performance liquid chromatography-tandem mass spectrometric
(LC-MS/MS) method was developed and validated for determination of lovastatin in human plasma, using lovastatin-d3
as an internal standard. Lovastatin and lovastatin-d3 were extracted from human plasma using solid phase extraction,
separated on Luna C18 (2)100A (100 × 4.6 mm, 5 μm) column with mobile phase consisting of acetonitrile and 2 mM
ammonium acetate buffer (pH 3.6) in the ratio of 90:10, v/v. Quantification was achieved by monitoring transitions of
m/z 422.1→ 285.4 for lovastatin and 425.4→ 285.4 for lovastatin-d3 in multiple reaction monitoring, using turbo ion
source in positive polarity.
Results: No matrix effect was observed within the linearity range of 0.121–35.637 ng/mL (r > 0.99). The degree of matrix
effect for lovastatin was determined as 2.74 %, and it had no impact on incurred samples analysis with run time of
4.5 min. The intra- and inter-day precision values were within 11.38 and 8.62 % respectively, for lovastatin at the lower
limit of quantification level.
Conclusions: Stability data indicated that lovastatin is stable under various handling conditions and with insignificant
inter-conversion between lovastatin and lovastatin hydroxy acid. The method was successfully applied for the
bioequivalence study of lovastatin after oral administration of 40 mg tablet in healthy volunteer.
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Lovastatin is a cholesterol-lowering agent, used in the treat-
ment of hypercholesterolemia. It is a lactone, which hydro-
lyzes readily in vivo to its β-hydroxy acid form, an inhibitor
of 3-hydroxy-3-methylgluteryl-coenzyme A (HMG-CoA)
reductase. HMG-CoA reductase catalyzes the conversion
of HMG-CoA to mevalonate, which finally converted to
cholesterol by subsequent biochemical pathways. Thus,
inhibition of the HMG-CoA reductase activity limits the
biosynthesis of cholesterol (Hsu et al. 1995; O’Connor et al.
1990). Following an oral dose of lovastatin, only about 30 %* Correspondence: arabinda.saha@ranbaxy.com
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plasma concentration in 2.0 h. It has protein binding of
about 95 % (Mevacor®, Prescribing Information, 2012). It
undergoes extensive first-pass metabolism in the liver,
because of which the availability of the drug to the general
circulation is low and variable. The metabolites of
lovastatin in human plasma are 6′β-hydroxy acid lova-
statin, 6′-exomethylene lovastatin, and 3″-hydroxy lova-
statin (Jacobsen et al. 1998). Hydroxylation of lovastatin at
6′ position also occurs in ex vivo. Therefore, a sensitive
and specific analytical method is required for the estima-
tion of lovastatin in human plasma with optimized
conditions, wherein inter-conversion between lactone and
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for the determination of lovastatin, but the sensitivity of
published HPLC-UV methods (Islam et al. 2010; Lin et al.
2004; Lily et al. 2000; Mullangi et al. 2006; Strode et al.
1999) are inadequate for pharmacokinetic study and thera-
peutic drug monitoring. In the reported gas chromatog-
raphy–mass spectrometric method (Morris et al. 1993), the
sensitivity was improved by derivatization, but it is a time-
consuming process. LC-MS/MS methods (Dong et al.
2008; Haiyan et al. 2008; Lin et al. 2008; Nageswararao
et al. 2012; Ramakrishna et al. 2007; Xiao et al. 2006; Xiu
and Chris 2003; Wu et al. 1997) have also been reported
with increased sensitivity but the inter-conversion between
lovastatin to lovastatin hydroxy acid has not been studied
in these methods, which could lead to pseudo estimation
of lovastatin in plasma. Although the kinetics of in vitro
inter-conversion between lactone and its hydroxy acid
form has been reported by Kearney et al. (1993) and Won
(1994), its application for the estimation of lovastatin in
the bioequivalence study has not been reported till date.
The developed method has numerous advantages over
other existing methods. The pros of the developed method
includes the following: less aliquot volume compared to
methods developed by Xiao et al. (2006), Lin et al. (2008),
and Nageswararao et al. (2012); better sensitive compared
to methods developed by Lily et al. (2000), Mullangi et al.
(2006), and Islam et al. (2010); inhibiting the in vitro inter-
conversion between lovastatin and lovastatin hydroxy acid
results in accurate estimation of lovastatin in incurred
samples and this was not reported by Wu et al. (1997),
Lin et al. (2008), and Dong et al. (2008).
Methods
Chemicals and materials
Lovastatin (LS, Lot No.: H4K027, purity: 99.6 %), lova-
statin hydroxy acid (LHA, Lot No.: 13-MJC-79-1, purity:
89.5 %), and lovastatin-d3 (internal standard, IS, Batch
No.: CS-LS-455, purity: 97.87 %) were procured from the
United State of Pharmacopeia, Toronto Research Chemi-
cals Inc., Canada, and Clearsynth Labs (P) Ltd., India,Fig. 1 Chemical structures. a lovastatin, b lovastatin -d3, and c lovastatin hyrespectively (chemical structures are shown in Fig. 1). Am-
monium acetate and acetonitrile were procured from
Fluka (Sigma-Aldrich, Steinheim, USA). Glacial acetic acid
(analytical reagent) was obtained from Fischer Scientific,
India. Milli-Q water (Millipore, Moscheim Cedex, France)
was used in the preparation of solutions. Cleanert PEP-3,
30 mg/1 cc, solid-phase extraction (SPE) cartridges were
obtained from Agela Technologies (Tianjin, China). Hu-
man plasma lots containing K3EDTA (ethylenediaminetet-
raacetic acid tripotassium salt, as anticoagulant) were
obtained from Biological Specialty Corporation, PA, USA.
LC-MS/MS instrumentation and chromatographic conditions
Chromatographic separation was carried out on a
Shimadzu scientific instrument (Shimadzu Corporation;
Kyoto, Japan) with a Luna C18 (2) 100A column (100 ×
4.6 mm, 5 μm) (Phenomenex). A mobile phase consisting
of acetonitrile and 5 mM ammonium acetate buffer
(pH 3.6) in the ratio of 90:10, v/v, was delivered at a flow
rate of 0.7 mL/min. The total analysis run time for each
sample was 4.5 min. The ionization and detection were
carried out on a triple quadruple mass spectrometer, MDS
Sciex API-4000 (Sciex Division of MDS, Toronto, Ontario,
Canada), equipped with electrospray ionization operated
in positive polarity using multiple reaction monitoring
(+MRM). The compound and source parameters were op-
timized by infusing individual solution of LS, IS, and LHA
into the mass spectrometer. The optimized compound pa-
rameters for monitoring LS and IS were set as follows:
declustering potential (DP), 38 V; entrance potential (EP),
10 V; collision energy (CE), 20 V; and collision cell exit
potential (CXP), 7 V. The optimized compound parame-
ters for monitoring LHA were set as follows: DP 48 V, EP
5 V, CE 20 V, and CXP 8 V. The source parameters of the
mass spectrometer were optimized and maintained as fol-
lows: collision-activated dissociation (CAD) gas, 6 psi; cur-
tain gas (CUR), 20 psi; nebulizer gas (GS1), 60 psi; heater
gas (GS2), 40 psi; turbo ion spray voltage, 4500 V; and
source temperature, 450 °C. Quadrupole 1 and quadru-
pole 3 were both maintained at unit resolution, and dwelldroxy acid
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tions were selected as 422.1→ 285.4 for LS, 425.4→ 285.4
for IS, and 423.3→ 303.7 for LHA. The data acquisition
and processing were performed by Analyst version 1.4.2
software (MDS Sciex, Toronto, Canada). For quantifica-
tion, the peak area ratios of the target ions of the analyte
to those of the internal standard were compared with
weighted 1/X2 (where X = drug concentration) least
squares calibration curves in which the peak area ratios
of the calibration standards were plotted versus their
concentrations.
Preparation of stock solutions, calibration standards, and
quality control samples
Two separate stock solutions of LS were prepared for
bulk spiking of calibration standards (CS) and quality
control (QC) samples for method validation exercises as
well as incurred sample analysis. Stock solution of LS,
IS, and LHA were prepared in acetonitrile at concentra-
tion of 1 mg/mL. Working solutions for CS and QC
samples were prepared by appropriate dilution in
acetonitrile-water (50:50, v/v). Blank human K3EDTA
plasma was screened prior to spiking to ensure that
there is no significant endogenous interference at the re-
tention time (RT) of LS and its IS. An 8-point CS and
QC samples at four concentration levels were prepared
by spiking the blank plasma with an appropriate amount
of LS. CS were made at concentrations of 0.121, 0.328,
1.642, 4.105, 10.264, 17.106, 28.510, and 35.637 ng/mL
and QC samples at lower limit of quantification
(LOQQC), low-quality control (LQC), medium-quality
control (MQC), and high-quality control (HQC) at con-
centrations of 0.122, 0.359, 14.358, and 28.716 ng/mL,
respectively. To prevent inter-conversion between LS
and LHA, 3 % formic acid solution (v/v) was added in
spiked plasma in the ratio of 5:95 (v/v) during bulk spik-
ing. Spiking was carried out in ice-cold water bath under
low light condition, and bulk spiked CS and QC samples
were stored below −50 °C and protected from light till
use. The working solution of IS (150.0 ng/mL) for rou-
tine use was prepared by diluting the IS stock solution
in acetonitrile-water (50:50, v/v).
Sample preparation
Plasma sample (300 μL) was aliquoted, and 50 μL of IS
working solution (150.0 ng/mL of IS) was added in ice-
cold water bath and vortexed. To this sample, 500 μL
of 100 mM ammonium acetate buffer was added and
then samples were vortexed. The pretreated samples
were loaded onto the pre-conditioned cartridge (Clea-
nert PEP-3, 30 mg/1 cc) and spun in centrifugation at
4000 rpm for 1 min at 2–10 °C. The cartridges were
washed with 1 mL of 20 % methanol in water (v/v), and
analytes were eluted with 1 mL of acetonitrile. Theextracted samples were evaporated to dryness at 20 psi
and at 40 °C under a stream of dry nitrogen using a
Zymark TurboVap LV evaporator (Caliper, Hopkinton,
MA, USA). Dried residue was reconstituted with 300 μL
of reconstitution solution consisting of acetonitrile and
5 mM ammonium acetate buffer (pH 3.6) in the ratio of
60:40, v/v. The reconstituted samples of 20 μL volume
were used for injection in LC–MS/MS system.
Inter-conversion between LS and LHA
Role of temperature
Working solution of LS was spiked into human K3EDTA
plasma at LQC and HQC level. The spiked samples were
kept at different storage conditions ,i.e., room temperature
and ice-cold water bath to study the impact of temperature
on conversion of LS to LHA. After 6.0 h, four aliquots of
each samples stored at different conditions were processed
with freshly spiked CS and were analyzed in LC-MS/MS
system by monitoring both mass transitions of LS and
LHA in MRM.Role of pH
After evaluating the impact of temperature on conver-
sion, ice-cold water bath condition was maintained for
storing of plasma samples on bench. However, it was ob-
served that temperature is not a single parameter to
control the conversion, hence the role of pH on inter-
conversion was investigated in in vitro system. For this
purpose, separate working solutions of LS and LHA
were prepared in acetonitrile-water (50:50, v/v) and spik-
ing was carried out in following ways in human K3EDTA
plasma to attain concentration of 10.0 ng/mL for each
analyte:
a. Protocol-I (control-normal plasma)
b. Protocol-II (acidified plasma, pH 6.0 adjusted with
formic acid solution)
c. Protocol-III (acidified plasma, pH 4.0 adjusted with
formic acid solution)
Spiked samples were kept in ice-cold water bath and
under low light condition, and four aliquots of these sam-
ples were processed at time intervals 0.0, 2.0, 4.0, and
6.0 h and were analyzed in LC-MS/MS system by moni-
toring both mass transitions of LS and LHA in MRM.
Method validation
A thorough and complete method validation of LS in hu-
man K3EDTA plasma was carried out, as per the USFDA/
EMEA guidelines (USFDA bioanalytical guideline 2001 and
EMEA bioanalytical guideline 2011). The method was
validated for selectivity, sensitivity, linearity, precision,
accuracy, process efficiency, dilution integrity, matrix effect,
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short-term sample processing and long-term storage.
The selectivity of the method towards endogenous
plasma matrix components, metabolites, and concomitant
medications was assessed after screening ten lots (6 normal,
2 haemolyzed, and 2 lipemic) of human K3EDTA plasma,
free from all analyte of interest. These samples were proc-
essed using the proposed extraction protocol and analyzed
with the set chromatographic conditions of LS at lower
limit of quantification (LOQ) level. The peak area of the
co-eluting components or interferences in blank sample at
the retention time of LS and IS should be less than 20 and
5 % of mean peak area of LS and IS in spiked LOQ sample,
respectively. The sensitivity was demonstrated by determin-
ing the signal to noise (S/N) ratio in all ten lots of screened
plasma and spiked LOQ samples. The S/N ratio of spiked
LOQ samples was calculated using following formula:
S
N
ratio ¼ Signal to noise ratio of LOQ
Mean signal to noise ratio of blanks
> 5
Three calibration curves were used to demonstrate the
linearity of the method. The ratio of area responses for
lovastatin was used for regression analysis. Each calibra-
tion curve was analyzed individually by using least square
weighted (1/X2) linear regression (obtained by best fit
method). Back calculations were made from these curves
to determine the concentration of lovastatin in each cali-
brator. A correlation coefficient r > 0.99 was desirable for
all the calibration curves. The analyte peak of LOQ sam-
ple should be identifiable, discrete, and reproducible with
a precision (% CV) of <20.0 and accuracy within ±20.0 %.
The deviation of standards other than LOQ from the
nominal concentration should not be more than ±15.0 %.
The intra- and inter-day precision and accuracy were
performed for lovastatin in K3EDTA plasma. The intra-
run (within a day) and inter-run (between days) accuracy
was determined by replicate analysis of QC samples (n =
6) at LOQQC, LQC, MQC, and HQC. The precision of
the method was determined by calculating the coefficient
of variation (% CV) for each QC level. The deviation at
each concentration level from the nominal concentration
was expected to be <15.0 except for the LOQQC, for
which it should be <20.0. Similarly, the mean accuracy
should be within ±15.0 % except for at the LOQQC, for
which it should be ±20.0 % of the nominal concentration.
The process efficiency (PE) for LS and IS at low, mid-
dle, and high QC concentration levels were determined
by measuring the mean peak area response of LS in six
replicates of extracted QC samples (spiked before ex-
traction) against the mean peak area response of LS in
unextracted samples (neat samples) containing LS and
IS at concentrations equivalent to those obtained in the
final extracted concentration for LS and IS in the QCsamples. Process efficiency (PE) of LS and IS were esti-
mated by using the following equation:
% PE ¼ Mean peak area of analyte in extracted samples
Mean peak area of analyte in neat sample solution
 100
The absolute matrix effect (AME) was estimated by
the following equation:
% AME ¼ Mean peak area of analyte in post extracted samples
Mean peak area of analyte in neat solution
 100
where AME = 1 indicates no matrix effect, AME < 1
indicates ion-suppression, and AME > 1 indicates ion en-
hancement. As extraction protocol involved a terminal
drying step, hence spiking (addition of reference sam-
ples) was carried out in post-extracted blank plasma
sample to perform AME. The concentration of LS and
IS in reference sample representing the QC concentra-
tion (at LQC, MQC, and HQC level). The control sam-
ple was a reference solution prepared at appropriate
concentration in a reconstitution solution.
Relative matrix effect (RME) was evaluated using six
lots of human K3EDTA plasma including one hemolyzed
and one lipemic plasma lot, processed in duplicate sam-
ples at LOQQC and HQC levels and the area ratio (i.e.,
peak area response of LS/peak area response of IS) was
used to check the acceptability of the result. The standard
deviation for each lot was calculated, along with % CV and
% bias at each level. The deviation of the standards should
not be more than ±15 % of their respective nominal con-
centration, and at least 90 % of the lots at each QC level
should be within the aforementioned criteria.
Stability experiments were carried out to examine the sta-
bility of LS in stock solution and in plasma samples under
different conditions. Stock solution stability was performed
by comparing peak area response of LS and IS in stability
sample, with the peak area response of sample prepared
from fresh stock solution. Stability studies in plasma were
performed at LQC and HQC level using four replicates at
each level. The analyte was considered stable if the %
change is less than 15, as per US FDA/EMEA guidelines
and was calculated by using the following formula:





Where S =mean concentration of stability samples and
F =mean concentration of freshly spiked samples.
The bench top stability was determined by stored
spiked QC samples for ~6.5 h in ice-cold water bath be-
fore processing. The autosampler stability was deter-
mined by stored reconstituted QC samples for ~72 h
under autosampler condition (at 10 °C) before being
analyzed. The freeze-thaw stability was conducted by
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−50 °C and thawed at room temperature three times, with
freshly spiked QC samples. Four aliquots each of LQC
and HQC concentration level were used for the freeze-
thaw stability evaluation. For long-term stability evalu-
ation, the concentrations obtained after 121 days were
compared with initial concentrations. All stability exer-
cises were performed against freshly spiked CS.
Human K3EDTA whole blood spiked with working so-
lutions (at LQC and HQC level) were prepared and after
spiking spiked sample was split into two aliquots (A and B).
Aliquot A was placed for 10 min in ice-cold water bath,
centrifuged at 4 °C, and the resulting plasma was used as
comparison sample. Aliquot B was kept in ice-cold water
bath for 2.0 h, centrifuged at 4 °C, and the resulting plasma
(stability samples) was analyzed with the comparison
samples in the same batch to access the % stability dur-
ing the sample collection process. The analyte (LS) was
considered stable if the % stability is 85–115 and was
calculated by using following formula:
% stability ¼ Mean area ratio of stability samples
Mean area ratio of comparison samples
 100
Re-injection reproducibility was performed by re-injecting
all QC samples (i.e., LOQQC, LQC, MQC, and HQC) from
an accepted precision-accuracy batch during validation. The
calculated concentration of re-injected QC samples was
determined against the CS samples from the same precision
and accuracy batch which was analyzed 48 h before.
The % difference between original and re-injected value was
calculated by using the following formula:
% difference ¼ Original concentration ‐ re‐injected concentrationj j
Original concentration
 100
The dilution integrity experiment was performed with an
aim to validate the dilution test to be carried out on higher
analyte concentrations above upper limit of quantification
(ULOQ), which may be encountered during real incurred
sample analysis. Dilution integrity test was performed by
preparing samples at a concentration approximately two
times the concentration of 90 % ULOQ. These samples
were diluted to two and four times with blank plasma to
bring the concentration within calibration curve and then
analyzed against fresh CS samples. The acceptance criteria
for the diluted QC samples are the same as that of QC
samples in precision and accuracy run.
Method application
The method was applied to an open-label, balanced,
randomized, two-treatment, four-period, two-sequence,
single dose, crossover design study of lovastatin in
healthy human volunteers under fed condition for the
assessment of bioequivalence. A single oral dose oflovastatin 40-mg tablet of Ranbaxy and Medostatin 40-
mg tablet of Medochemie Limited, Cyprus, marketed by
Kodomedic sdn. Bhd, Malaysia, was given to the human
volunteers during the study. The bio-study was carried
out in accordance with the principles of Good Clinical
Practices defined in the ethical guidelines for Biomedical
Research on human participants issued by Indian Coun-
cil of Medical Research, New Delhi, the ICH E6 Guid-
ance for ‘Guidance on Good Clinical Practice,’ and the
principles enunciated in the Declaration of Helsinki on
36 healthy volunteers from whom prior informed con-
sent was taken. The bio-study protocol was approved by
the Jamia Hamdard Institutional Review Board, New
Delhi, India. Blood samples were collected at 0.500,
1.000, 1.333, 1.667, 2.000, 2.333, 2.66, 3.000, 3.333,
3.667, 4.000, 4.333, 4.667, 5.000, 6.000, 9.000, 12.000,
16.000, 24.000, 36.000, and 48.000 h post dose in each
period. All blood samples were collected in K3EDTA
vacutainers and processed by centrifugation to collect
plasma and stored below −50 °C until analysis.
Incurred sample reanalysis (ISR) reinforces the confi-
dence in a bioanalytical method by demonstrating re-
producibility in the measurement of study data. The
possible causes of irreproducibility in ISR can be due to
many reasons, which may include the following: stabil-
ity issues - conversion of metabolite to its parent com-
pound, isomeric changes, or effect of pH; drug-protein
binding differences in subject samples; issues related to
matrix interference - general and those associated with
phospholipids; concomitant medications; sample pro-
cessing technique - variations in process efficiency.
Therefore, reproducibility of the method was confirmed
by performing ISR. ISR was assessed using a total of
201 sample sets, selected from 31 subjects who com-
pleted all four periods of the study. The incurred sam-
ples from a Cmax time point and elimination phase (at
least three times of LOQ concentration) comprising of
80 % sample set and the remaining 20 % as random
sample time points were selected. The acceptance cri-
terion for the ISR analytical run was 67 % (two-thirds
of the total sample size) and should lie within 20 % dif-
ference (Viswanathan et al. 2007). The % difference
from the original analysis was calculated as:




Optimization of mass parameters and chromatographic
conditions
Lovastatin is reported to be highly variable drug in terms
of pharmacokinetics (PK) behavior with low Cmax value.
For accurate and reliable characterization of PK profile,
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LOQ (0.1 ng/mL) for 40 mg strength. In order to de-
velop a method with the desired LOQ, it was necessary
to use MS-MS detection.
Even though LS has a carboxylic acid moiety, electro-
spray ionization in negative polarity was less sensitive
than the positive polarity. Initially, mass parameters
were also tuned in atmospheric pressure chemical
ionization (APCI) and electrospray ionization (ESI) ion
sources, but inadequate response was observed in APCI
ion source. Various adducts have been reported in
positive polarity to further increase the sensitivity of
lactone (Wu et al. 1997; Daniel et al. 2000). Use of am-
monium acetate solution in mobile phase helped in the(a
(b
(c
Fig. 2 MSMS spectra. a LS, b IS, and c LHAformation of ammonium adducts of LS [M + NH4]
+
which increased sensitivity of the method by 20 folds.
Ammonium adduct was selected as parent ion, m/z
422.1. During the product ion scan, the major product
ions at m/z 199, 225, 239, 267, and 285 were observed.
Based on the signal intensity of the product ion of m/z
285.4 which was generated by loss of ester side-chain
and H2O from the parent ion, it was selected as a prod-
uct ion for LS and transition of m/z 425.4→ 285.4 was
selected for IS in MRM mode. During optimization, it
was observed that CE and CAD are the most critical
parameters to achieve highest sensitivity and stable re-
sponse for LS. Product ion spectra of LS, IS, and LHA
are shown in Fig. 2.)
)
)
Table 1 Role of temperature on inter-conversion (n = 4)
A B
QC sample % accuracy Protocol-A Protocol-B
Protocol-A Protocol-B A1 A2 A1 A2
LQC (0.359 ng/mL) 84.25 ± 1.86 61.37 ± 0.82 22,140 2015 16,470 2514
HQC (28.716 ng/mL) 86.07 ± 3.44 68.87 ± 3.40 1,704,693 68,417 1,413,647 82,503
Protocol-A: Samples were kept in ice-cold water bath for 6.0 h. Protocol-B: Samples were kept at room temperature for 6.0 h
A1 mean peak area observed at RT of LS (m/z: 422.1→ 285.4), A2 mean peak area observed at RT of LHA (m/z:423.3→ 303.7) both in positive ion mode
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phenyl columns like Poroshell 120 EC-C18, Ascentis
express, Sunshell C18, Kinetex C18, Hypurity advance,
Zorbax SB-C18, Discovery C18, Unisol C18, Luna
C18(2), kinetex PFP, and ACE C18 PFP were tried.
Many columns with fused core technology were also
evaluated to attain resolution between LS and LHA,
but due to high back pressure, these columns could not
be used. LS and LHA were chromatographically well
separated on Luna C18 (2) 100A (100 × 4.6 mm, 5 μm)
column with high S/N ratio for LS. This could be due
to lower carbon loading of the column, enabling the se-
lectivity by base material of the column, and lower carbon
load reduces RT of analyte and increased high throughput.
The use of methanol as an organic phase led to high back-
pressure, and high aqueous portion in mobile phase sup-
pressed the peak area response of LS. However, the
mixture of ammonium acetate buffer and acetonitrile
(90:10, v/v) was found optimal, with very low background
noise and optimum back pressure. In addition, mobile
phase with high organic solvent ratio increased the
ionization efficiency of LS. The analytes (i.e., LS and LHA)
were chromatographically separated from phospholipids
and other endogenous components at pH 3.6, which was
attained by the addition of glacial acetic acid in ammo-
nium acetate buffer. The absence of co-eluting peaks asTable 2 Role of pH in plasma on inter-conversion (n = 4)
Analysis of LS spiked sample (10.0 ng/mL)
Duration Normal plasma Acidified plas
A1 A2 A1
0.0 h 588,767 14,529 722,551
2.0 h 565,406 21,013 718,763
4.0 h 533,753 25,785 729,776
6.0 h 482,788 27,854 716,005
Analysis of LHA spiked sample (10.0 ng/mL)
Duration Normal plasma Acidified plas
A1 A2 A1
0.0 h 9642 37,598 2034
2.0 h 13,925 33,423 2496
4.0 h 16,780 33,168 2738
6.0 h 19,962 31,313 2568
A1 mean peak area observed at RT of LS (m/z: 422.1→ 285.4), A2 mean peak area owell as interference from matrix ions was minimal with a
Luna C18 (2) column in combination with mobile-phase
ammonium acetate buffer and acetonitrile (90:10, v/v).
Selection of IS
In LC-MS/MS analysis, selection of IS with similar chro-
matographic and mass spectrometric behavior to that of
analyte is of utmost priority. The best IS is a stable iso-
tope form of the analyte which proves to be helpful
when significant matrix effect is possible. Therefore,
lovastatin-d3 was selected as an IS.
Role of temperature and pH on inter-conversion
The stability QC samples which were stored in ice-cold
water bath showed higher % accuracy as compared to
those QC samples stored at room temperature (Table 1).
This indicated that the rate of degradation of LS to
LHA was facilitated at room temperature. Upon storing
of spiked samples at room temperature, LS peak area
decreased by 25.6 and 17.0 % at LQC and HQC level,
respectively, when compared with samples stored in
ice-cold water bath condition, whereas LHA peak area
increased approximately by 1.24 times (Table 1).
Although the % accuracy of stability QC samples
which were stored in ice-cold water bath (protocol-A)












bserved at RT of LHA (m/z:423.3→ 303.7) both in positive ion mode
Fig. 3 Representative chromatograms. a Blank, b blank processed with internal standard, c LOQ, d ULOQ, and e incurred sample
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conversion pathway for LS to LHA was not blocked in
ice-cold water bath condition. Hence, the role of pH on
in vitro inter-conversion of LS and LHA was investi-
gated. From Table 2 data, we could conclude that pHTable 3 Intra-and inter-run results




LOQQC (0.122 ng/mL) 97.34 98
LQC (0.359 ng/mL) 103.74 10
MQC (14.358 ng/mL) 102.88 10
HQC (28.716 ng/mL) 102.94 10
an = 6, expressed as 100 ×mean calculated concentration/nominal concentration
bValues obtained from all three runs (n = 18)
cn = 6has a prime role in controlling the inter-conversion
between LS and LHA in plasma. In normal plasma (at
pH 7.4), LS gets converted to LHA and at pH 4.0, LHA
gets converted to LS. The rate of conversion is increased










Table 4 Absolute matrix effect and process efficiency of lovastatin
QC sample Aa (% CV)b Bc (% CV)b Cd (% CV)b Absolute matrix effect (% AME)e Process efficiency (%PE)f
LQC 35,950 (3.6) 35,521 (4.3) 27,239 (4.1) 98.81 75.77
MQC 1,415,891 (1.6) 1,406,632 (4.3) 1,130,372 (7.3) 99.35 79.83
HQC 2,716,145 (0.9) 2,641,614 (0.8) 2078,894 (1.8) 97.26 76.54
aMean area response of six replicate samples prepared in reconstitution solution
bCoefficient of variation
cMean area response of six replicate samples prepared by spiking in extracted blank plasma sample
dMean area response of six replicate samples prepared by spiking before extraction
eB/A × 100
fC/A × 100
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change in mean peak area response for both analytes with
respect to time. So based on these results, we concluded
that both pH and temperature have a role on inter-
conversion. Finally, pH 6.0 and ice-cold water bath con-
dition were maintained for spiked samples to inhibit
the inter-conversion.
Sample preparation
The samples pretreated with 100 mM ammonium acet-
ate buffer solution were extracted using SPE cartridge.
This extraction procedure gave higher PE and cleaner
sample. Due to hydrophobic nature of LS, different poly-
meric cartridges like Oasis HLB, Bond Elut Plexa, Cleanert
PEP-H, and Cleanert PEP-3 were tried during method
development. The high PE and consistent results were
obtained in sample prepared using Cleanert PEP-3 car-
tridges. Inconsistency in peak area response of LS and
IS was observed during analysis of extracted samples.
This could be due to low solubility of LS and IS in the
mobile phase that was finalized during chromatographic
optimization. Low solubility of LS and IS could be due to
the high hydrophobic nature of these compound, which
led to suppressed LS and IS peak area response in the ex-
tracted samples. Therefore, the reconstitution solution
composition was further optimized and it was observed
that reconstitution solution consisting acetonitrile 2 mMTable 5 Relative matrix effect of lovastatin








Lot-1 0.121 (1.2) −0.82 28.799 (0.20) 0.29
Lot-2 0.122 (5.2) 0.00 28.632 (0.00) −0.29
Lot-3 0.126 (4.5) 3.28 28.145 (1.80) −1.99
Lot-4 0.118 (0.6) −6.56 29.527 (0.70) 1.14
Lot-5c 0.114 (4.4) −3.28 29.042 (0.80) 2.82
Lot-6d 0.121 (4.1) −0.82 28.960 (0.40) 0.85
aMean of duplicate observations at each concentration
bCoefficient of variation
cHemolyzed plasma
dLipemic plasmaammonium acetate (pH 3.6) buffer (60:40, v/v) was suit-
able for solubility of LS and IS and gave consistent IS peak
area throughout the analytical batch of larger sample size.
Method validation
There was no significant interference observed at the RT
of LS and IS in screened plasma lots. The typical chro-
matograms of blank sample, blank processed with IS,
LOQ, and ULOQ, and incurred sample in human
plasma are shown in Fig. 3. We observed that S/N ra-
tio was >25 during method validation and incurred
sample analysis, which was within acceptable limit as
per the USFDA/EMEA guidelines.
The limit of quantitation was 0.121 ng/mL of LS in
plasma. The precision and accuracy at LOQQC level were
8.62 and 98.12 %, respectively. The calibration curve was
linear from 0.121 to 35.637 ng/mL for LS in plasma. Cali-
bration curve was constructed using peak area ratio of an-
alyte to internal standard and by applying linear, weighted
least squares regression analysis with weighting factor of
1/(concentration)2. The ‘r’ was greater than 0.99 during
the course of precision and accuracy batches. The results
of three precision and accuracy batches are summarized
in Table 3. The intra-day precision and inter-day precision
(% CV) ranged from 1.73 to 11.38 %, and the intra- day
and inter-day accuracy ranged from 97.34 to 103.74 %.Table 6 Stability of lovastatin in different storage conditions
(n = 4)
Stability Level A % CV B % CV % change
Autosampler stability
(~76.90 h, 10 °C)
LQC 0.358 7.00 0.359 1.57 −1.95
HQC 28.832 1.27 28.716 1.38 1.36
Bench top stability
(~8.82 h, in ice-cold
water bath)
LQC 0.358 1.46 0.359 2.60 2.64




LQC 0.358 1.46 0.359 2.75 2.05




LQC 0.358 2.35 0.359 2.43 0.00
HQC 28.832 0.63 28.716 0.96 3.94
A comparison sample concentration (ng/mL), B stability sample concentration
(ng/mL), CV coefficient of variation
Table 7 Pharmacokinetic parameters of lovastatin, after
administration of an oral dose of 40 mg of lovastatin test and
reference formulation of 31 healthy human volunteers
(Mean ± SD)
Parameters Test Reference
Tmax (h) 3.12 ± 1.28 2.89 ± 1.26
Cmax (ng/mL) 16.13 ± 7.18 16.68 ± 7.36
AUC0→t(h.ng/mL) 81.25 ± 34.53 88.73 ± 37.66
t 1/2 (h) 3.12 ± 1.28 2.89 ± 1.26
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electro spray ionization mass spectrometry, which influ-
ences the ionization of analyte by ion suppression or en-
hancement. The % CV of AME at QC level was in range
of 0.84–4.50, and between three QC levels, it was 1.31.
The results indicated there was no significant matrix ef-
fect for analyte, followed by the extraction procedure of
the method. The PE of LS and IS were consistent across
the QC levels. The mean PE of LS and IS by the method
were 77.38 and 75.04 %, respectively. The % CV of mean
PE across the low, middle, and high QC levels was <3.
The results of AME and PE are presented in Table 4,
and relative matrix effect (RME) results are presented
in Table 5.
Stock solution stability of LS and IS were established
for 13 days at specified conditions and % stability of
LS and IS were 102.01 and 101.67, respectively. LS was
proved to be stable in plasma for three freeze-thaw
cycles. Bench top stability of LS was established for
8.82 h in human plasma in ice-cold water bath and
under low light conditions. Autosampler stability was
assessed for 76.90 h, and long-term stability was
established at −50 °C for 121 days. The observed meanFig. 4 Plasma concentration profile. Linear plot of mean plasma concentra
drug; T1, T2: test drugnominal concentration of LS was found to be within
±15 % of their respective nominal concentration and %
CV was less than 15 at LQC and HQC levels (Table 6).
Lovastatin was stable in human K3EDTA whole blood
for ~2.0 h.
Re-injection reproducibility of LS was established by
re-injecting QC samples of precision and accuracy
batch-3 and quantitated against original analyzed cali-
bration curve of precision and accuracy batch-3. The %
differences for all re-injected QC samples are ≤7.45.
Method application
Following analysis, pharmacokinetic parameters like peak
plasma concentration (Cmax), time (Tmax) to reach Cmax,
t1/2, and (AUC0→t) were calculated by non-compartmental
analysis using WinNonlin Professional software (version
5.0, Pharsight Corp., Mountain View, CA, USA). The
pharmacokinetic parameters summarized in Table 7 are
the mean estimates obtained from 31 subjects, who com-
pleted all periods of the study. The linear plot of mean
plasma concentration (ng/mL) versus time (h) is shown
in Fig. 4. ISR results demonstrated that the samples with
percentage difference within ±20 % was 97.01 %.
Conclusions
In summary, a rapid, selective, specific, reproducible,
and high-throughput LC-MS/MS method was developed
and validated to estimate lovastatin in human plasma
using lovastatin-d3 as an internal standard. The proposed
method showed good performance with respect to all the
validation parameters tested, demonstrated optimized
working conditions for lovastatin in human plasma with
minimal inter-conversion, and was successfully employed
for a bioequivalence study of lovastatin after oral adminis-
tration of 40-mg tablet.tion (ng/mL) versus time (h) of lovastatin (n = 31); R1, R2: reference
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